OPRX, US68401U2042

OptimizeRx stock gained 1.03 percent on October 6

Published on 10/07/2026 at 07:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

OptimizeRx stock gained 1.03 percent on October 6, while B. Riley raised its target from USD 10 to USD 11. Q2 revenue fell to USD 20.504 million.

OPRX, US68401U2042, Illustration mit AI erstellt.

OptimizeRx stock (ISIN US68401U2042) was last at USD 8.81 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, up 1.03 percent from the prior close. The move comes as investors weigh a weaker second-quarter revenue trend against new distribution opportunities for the digital health platform.

Revenue fell in Q2 2026

According to Simply Wall St on October 4, 2026, OptimizeRx reported Q2 2026 revenue of USD 20.504 million, down from USD 29.195 million in Q2 2025. Net income changed from a USD 1.532 million profit to a USD 0.703 million loss, while net margin moved from 5.2 percent to negative 3.4 percent.

The figures leave the stock reliant on execution rather than top-line momentum. OptimizeRx generated USD 8.611 million in operating cash flow in Q2 2026, while cash stood at USD 24.096 million at June 30, 2026.

New channels broaden the platform

According to GlobeNewswire on September 22, 2026, OptimizeRx integrated its point-of-care inventory with The Trade Desk's OpenPath. The arrangement connects advertisers with more than 400 electronic health record and e-prescribing systems and 800,000 verified healthcare professionals.

The inventory is expected to become available through OpenPath in the fourth quarter of 2026. That timing gives the company a measurable operating checkpoint: new demand must translate into revenue after Q2 showed a USD 8.691 million year-over-year decline.

B. Riley target reaches USD 11

Markets Insider reported on September 29, 2026 that B. Riley raised its OptimizeRx price target from USD 10 to USD 11 and kept a Buy rating. The firm cited two revenue guidance cuts while EBITDA guidance held or increased, and described the DeepIntent electronic health record integration as a second growth engine for 2027.

The USD 11 target stands 24.9 percent above the USD 8.81 Nasdaq price. A separate assessment from Simply Wall St on October 4, 2026 placed fair values at USD 11 and USD 19 under different assumptions and highlighted privacy regulation and customer concentration as risks.

Stock remains below yearly high

OptimizeRx has a market capitalization of USD 165.3 million as of October 6, 2026, with 171,537 shares traded in the latest session. The 52-week range is USD 4.54 to USD 22.25, placing the latest price 60.4 percent below the high and 94.1 percent above the low.

For investors, the central test is whether the OpenPath rollout and audience tools can reverse the Q2 revenue decline while preserving cash generation. OptimizeRx stock was last at USD 8.81 on Nasdaq on October 6, 2026.